Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".
J Opioid Manag
; 17(7): 167-170, 2021.
Article
em En
| MEDLINE
| ID: mdl-34520038
Buprenorphine (BPN), FDA approved for opioid use disorder (OUD), requires an induction protocol for the patient in mild to moderate withdrawal. This can be problematic in outpatient practice due to complicated medical management. An emerging technique in literature uses a novel approach, called microinduction. In this method, escalating microdoses of BPN are administered, without requiring the patient to stop the opioid agonist. Our addiction treatment center used a microdosing technique to transit patients from methadone to BPN, without requiring opioid abstinence. Our case series is novel as it was outpatient microinduction from methadone to BPN in 7 days or less.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Buprenorfina
/
Transtornos Relacionados ao Uso de Opioides
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article